The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | Updates in treatments for HER2-positive GEA
Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the latest developments in the treatment for HER2-positive gastroesophageal adenocarcinoma (GEA). The MAHOGANY study (NCT04082364) evaluated a chemotherapy-free regimen composed of margetuximab, a HER2-targeting monoclonal antibody, and retifanlimab, an anti-PD-1 monoclonal antibody, and showed a response rate (RR) of 53% and a progression-free survival (PFS) reaching 6.4 months. These results support further investigation for chemotherapy-free treatment options. Moreover, the INTEGA study (NCT03409848) comparing chemotherapy-free immunotherapy with trastuzumab, nivolumab, and ipilimumab with the addition of nivolumab to FOLFOX chemotherapy and trastuzumab in the first-line setting in patients with previously untreated HER2-positive locally advanced or metastatic GEA showed limited efficacy for patients treated with the chemotherapy-free regimen. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
